Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Perrigo Company PLC (NYSE: PRGO), one of the world’s largest producers of over-the-counter self-care products, is entering the CBD business.

Perrigo Gets Into The CBD Business

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Why Is Perrigo (PRGO) Up 2.8% Since Last Earnings Report?

PRGO can effectively and cost efficiently produce generic drugs, competing with brand names.

Perrigo Company Has Strong Upside Potential Even In Times Of Uncertainty

Perrigo Company plc (PRGO) CEO Murray Kessler on Q1 2020 Results - Earnings Call Transcript

Perrigo (PRGO) reports decent first-quarter 2019 results. The addition of products following Ranir acquisition and stock piling due to COVID-19 boosts sales in the quarter.

Perrigo (PRGO) Surpasses Q1 Earnings and Revenue Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of 4.59% and 1.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Beats Q1 Earnings and Revenue Estimates

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Is a Beat in Store for Perrigo (PRGO) This Earnings Season?

DexCom

Haemonetics

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

3 Medical Product Stocks Set to Beat This Earnings Season: DXCM, HAE & PRGO

Perrigo (PRGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo (PRGO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results

Perrigo Co. PRGO, -1.03% said late Tuesday it experienced a first-quarter sales boost due to the COVID-19 pandemic.

Perrigo sees strong sales amid coronavirus pandemic

Why Is Perrigo (PRGO) Down 11% Since Last Earnings Report?

Abbott Labs

Baxter

Boston Scientific

Hill-Rom Hlds

Intuitive Surgical

Medtronic

ResMed

Stryker

Zimmer Biomet Hlds

Medical Products Industry Outlook: Growth Prospects Bright

Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter.

Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues

Perrigo Company plc (PRGO) CEO Murray Kessler on Q4 2019 Results - Earnings Call Transcript

Perrigo (PRGO) delivered earnings and revenue surprises of -2.75% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Lags Q4 Earnings Estimates

Perrigo Co. PLC PRGO, +0.00% reported Thursday a fourth-quarter adjusted profit that came up shy of expectations while sales were in line, while providing a downbeat full-year earnings outlook.

Perrigo profit comes up shy of expectations, revenue rises in line

Perrigo Co (NYSE: PRGO) announces its next round of earnings this Thursday, February 27.

Q4 Earnings Preview For Perrigo Co

Clovis Oncology

Eton Pharmaceuticals Inc

Immunomedics

vTv Therapeutics

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

Phibro Animal Health

PRGO vs. PAHC: Which Stock Is the Better Value Option?

PRGO or PAHC: Which Is the Better Value Stock Right Now?

Perrigo (PRGO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Perrigo (PRGO) Beat Estimates Again in Its Next Earnings Report?

PRGO vs. PAHC: Which Stock Should Value Investors Buy Now?

Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.

Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results

Investors responded positively to the drugmaker's sneak peek at its Q4 and full-year results.

Why Perrigo Shares Are Jumping Today

Shares of Perrigo Co. Plc PRGO, +8.47% rallied about 9% on Tuesday, after Leerink said sales guidance offered earlier in the day was strong.

News for Perrigo Stock (PRGO)